Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCKBR | P32239 | 14/20 | 0.83 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.76 |
| ▸ | NOTCH1 | P46531 | 2/20 | 0.66 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.66 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.66 |
| ▸ | RBPJ | Q06330 | 1/20 | 0.66 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.66 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.66 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.66 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.66 |
| ▸ | NOTCH3 | Q9UM47 | 1/20 | 0.65 |
| ▸ | CCKAR | P32238 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4414763 | 1.00 | CCKBR (0.83) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL7067691 | 1.00 | CCKBR (0.83) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL7066290 | 0.92 | CCKBR (0.70) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL4411431 | 0.92 | CCKBR (0.70) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL4412856 | 0.91 | CCKBR (0.80) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL6375205 | 0.91 | CCKBR (0.80) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL9868120 | 0.91 | CCKBR (1.00) | CCKBRKCNH2CCKAR | |
| SCHEMBL9868116 | 0.91 | CCKBR (1.00) | CCKBRKCNH2CCKAR | |
| SCHEMBL4422204 | 0.89 | CCKBR (0.67) | CCKBRKCNH2NOTCH1PSEN1PSEN2 | |
| SCHEMBL4412275 | 0.88 | CCKBR (0.75) | CCKBRKCNH2NOTCH1NOTCH3CCKAR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C | 2005-12-01 | — | — | US | disclosed |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2005-09-01 | — | — | US | disclosed |
| US-6906056-B2 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting β-amyloid peptide release and/or its synthesis by use of such compounds | ELAN PHARMACEUTICALS, INC. (US) | 2005-06-14 | — | — | US | disclosed |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | THOMPSON RICHARD C (US) | 2004-06-03 | — | — | US | disclosed |
| US-6569851-B1 | Treating Alzheimer's disease | ELAN PHARMACEUTIALS, INC. | 2003-05-27 | — | — | US | disclosed |
| EP-1089980-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | Elan Pharmaceuticals, Inc. (US) | 2001-04-11 | — | — | EP | disclosed |
| WO-2000047576-A1 | CINNAMIDE DERIVATIVES AS OREXIN-1 RECEPTORS ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2000-08-17 | — | — | WO | disclosed |
| WO-1999067221-A1 | COMPOUNDS FOR INHIBITING BETA-AMYLOID PEPTIDE RELEASE AND/OR ITS SYNTHESIS | ELAN PHARMACEUTICALS, INC. (US) | 1999-12-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267150-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 218/4885KCNH2 4568/4885NOTCH1 229/4885 |
| US-20050192265-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 218/4885KCNH2 4568/4885NOTCH1 229/4885 |
| US-20040106598-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting Beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 254/4885KCNH2 4610/4885NOTCH1 244/4885 |
| US-20050192269-A1 | Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds | BACE1, APP, BACE2 | CCKBR 218/4885KCNH2 4568/4885NOTCH1 229/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.